Ignite Creation Date:
2025-12-25 @ 1:26 AM
Ignite Modification Date:
2026-02-07 @ 9:51 AM
Study NCT ID:
NCT06617793
Status:
RECRUITING
Last Update Posted:
2025-10-23
First Post:
2024-09-26
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis
Sponsor:
Novartis Pharmaceuticals
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Relapsing Multiple Sclerosis | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Chimeric Antigen Receptor T cells | View |
| None | CAR-T | View |
| None | YTB323 | View |
| None | Multiple Sclerosis | View |
| None | MS | View |
| None | Relapsing Multiple Sclerosis | View |
| None | RMS | View |
| None | breakthrough disease activity during previous treatment with a highly efficacious … | View |
| None | BD-HET | View |